Drugs for Neglected Diseases initiative (DNDi) and four pharmaceutical firms, Eisai Co Ltd, Shionogi & Co Ltd, Takeda Pharmaceutical Ltd, and AstraZeneca plc have announced the start of a ground-breaking initiative to accelerate and cut the cost of ... PharmaBiz, 2 months ago
Drug Discovery Booster for neglected diseases - Laboratory News, 2 weeks ago
Removing Early Barriers To Drugs For Neglected Diseases - Asian Scientist, 1 month ago
* Market wants to wait until Greece's referendum - traders * China market moves focused - traders * Shionogi soars after Credit Suisse's rating hike By Ayai Tomisawa TOKYO, June 30 (Reuters) - Japan's Nikkei share average ...Yahoo! Finance, 1 month ago Nikkei rebounds on buybacks Japan Times, 1 month ago Nikkei edges up but Greece uncertainty still looms Hindu Business Line, 1 month ago Japan shares fluctuate as investors assess possible Greek fallout Malay Mail, 1 month ago
SHIONOGI : Findings on Alkylated Estrogenic Steroids Discussed by Investigators at Shionogi & Co. Ltd. (Dolutegravir Has No Effect on the Pharmacokinetics...
Findings on Alkylated Estrogenic Steroids Discussed by Investigators at Shionogi & Co. Ltd. (Dolutegravir Has No Effect on the Pharmacokinetics of Oral Contraceptives With Norgestimate and Ethinyl Estradiol) By a News Reporter-Staff News Editor ...4 Traders, 1 week ago
Shionogi Announces the Continued Expansion of their Operations in Europe with the Launch of Shionogi ItalyNoodls, 2 weeks ago
|Noodls, 3 weeks ago Shionogi to Issue of Stock Options as Compensation (Stock Acquisition Rights) to Members of Board of Directors Noodls, 1 month ago|
The HIV-oriented joint venture of Pfizer ($PFE), GlaxoSmithKline ($GSK) and Japan's Shionogi is turning to a Chinese manufacturer for a cheap supply of dolutegravir, the active ingredient in its Tivicay. The deal is seen as a way to cut the cost in ...IChainnel, 4 weeks ago
First developed by Shionogi Inc. under the code name of S-4522 at the end of 1980s, rosuvastatin (rosuvastatin calcium) along with its development, marketing and sales rights, was transferred to AstraZeneca in Jun. 1998 under the code name of ...MarketResearch.com, 1 month ago
SHIONOGI ANNOUNCES THAT NALDEMEDINE MET THE PRIMARY ENDPOINT IN ITS FIRST JAPANESE PHASE 3 STUDY FOR THE TREATMENT OF OPIOID-INDUCED CONSTIPATION IN CANCER PATIENTSNoodls, 1 month ago
Research and Markets (http://www.researchandmarkets.com/research/jqnh8b/thrombocytopenia) has announced the addition of the "Thrombocytopenia - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the ...Individual.com, 13 hours ago Research and Markets: Thrombocytopenia Pipeline Review, H1 2015 - 35 Companies & 41 Drug Profiles BioMedReports, 12 hours ago Global Opioid-Induced Constipation Market Report 2015-2019 - Shift to Targeted Therapy with AstraZeneca, Takeda Pharmaceutical & Valeant Pharmaceuticals International Dominating Ulitzer, 1 week ago Opioid-Induced Constipation Market to Grow at 30% CAGR by 2019 Says a New Research Report at ReportsnReports.com July 10, 2015The Global Opioid-Induced Constipation Market 2015-2019 report says the shift to targeted therapy is the latest trend observed i PRWeb, 6 days ago
An unprecedented global initiative is helping to develop and fast-track drugs for diseases mainly affecting the poor. Research and development for new medicines is costly, time-consuming and almost always profit driven. So when a disease ...Al Jazeera, 14 hours ago
on your WebpageAdd Widget >Get your members hooked!